Navigation Links
Awareness of Genzyme's Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
Date:5/23/2008

EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Renvela report, the second in a multi-phase syndicated market research project tracking the launch of Renvela from baseline awareness through the first six months of product availability. The baseline report was published in December 2007. Wave 1 was fielded in April 2008, one month post Renvela launch, and provides quantitative information from 30 clinical Nephrologists and 30 Renal Dietitians (RDs) in the US, and qualitative information from a subset of 15 respondents in each group.

While virtually all Nephrologists and RDs are aware of Renvela, the next generation Renagel (sevelamer hydrochloride), the vast majority have not yet tried the new phosphate binder. Reimbursement is currently the biggest obstacle to use. Genzyme representatives seem to have increased their contact frequency compared to competitors in their promotion of this new product -- most often focusing on Renvela's similarity to Renagel but with fewer incidences of acidosis and better GI tolerability, according to Nephrologists and RDs. Renvela trials for the most part have been in patients switched from Renagel or naive to binder therapy, although depending on patient types, there are switches from competitive products. Each binder is associated with a variety of attributes and each is associated with unique concerns. Renvela is currently perceived to be the best choice for patients with metabolic acidosis.

Despite slower uptake than MDs and RDs predicted in the baseline research, Renvela share is expected to increase in the next six months among both dialysis and CKD patients.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact Jennifer Robinson at (610) 363-3872 or jrobinson@bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
2. CDC Awards NATT Funding to Improve Blood Clot Awareness
3. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
4. Answers.coms WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month
5. SleepQuest Raises Awareness of Sleep Disorders
6. Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness
7. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
8. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
9. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
10. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... commercializing its flagship CytoSorb® blood filter to treat ... around the world, announced that CEO Dr. ... the Source Capital Group,s 2016 Disruptive Growth & ... the company.  Conference Presentation Details: ...
(Date:2/4/2016)... BETHESDA, Md. , Feb. 4, 2016  Spherix ... committed to the fostering and monetization of intellectual property, ... VTech and Uniden in the Northern District of ... are moving forward.  Inter Partes ... the U.S. Patent Office.  The IPR was initiated on ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
Breaking Biology News(10 mins):